Indiana University Vector Production Facility

Indianapolis, IN
Find alternatives to Indiana University Vector Production Facility for AAV →
National Center
49 confirmed programs · 12 sponsors · Last scored 2026-10-29
66.3
Signal Score
○ FDA Inspections ✓ Clinical Trials (49) ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Indiana University Vector Production Facility

Signal Score
66.3/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Indianapolis, IN
Modalities
AAV, Lentiviral
Active Programs
49 confirmed from ClinicalTrials.gov across 12 sponsors
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Indiana University Vector Production Facility

CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations 71.7
49 active programs across 12 sponsors
Modalities: AAV, Lentiviral
18 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov
49 active programs across 12 sponsors · Modalities: AAV, Lentiviral · 18 programs in advanced phases (Phase 2/3)
Programs 49
Sponsors12
ModalitiesAAV, Lentiviral
49 active programs across 12 sponsors
Modalities: AAV, Lentiviral
18 programs in advanced phases (Phase 2/3)
Source: ClinicalTrials.gov facility matching
NCT07168785 [18F]-AraG PET Imaging in LA HNSCC EARLY_PHASE1 Not Yet Recruiting
NCT07761910 Prospective Study on Radiation Induced Cardiotoxicity... PHASE2 Recruiting
NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 NA Recruiting
NCT07708714 Optimizing Hydroxyurea Therapy in Children With Sickle Cell... PHASE1/PHASE2 Recruiting
NCT07640139 Estimating the Impact of Obesity Medications on Clinical and... NA Enrolling By Invitation
NCT06915038 ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx NA Recruiting
NCT06508827 Intravenous Iron in Combination With Standard of Care... PHASE2 Withdrawn
NCT06513663 Exercise as Maintenance Therapy in Advanced Lung Cancer NA Terminated
NCT05757843 Using Circulating Tumor DNA to Personalize Duration of... PHASE2 Withdrawn
NCT05899166 Carbohydrate Beta Cell Function and Glucose Control in... NA Recruiting
View all 49 programs →
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026
Financial Stability 68.0
Parent company: Indiana University
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Indiana University
Financial assessment: 68.0/100
Capacity 58.0
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100
Sites: Indianapolis, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Indianapolis, IN
Modalities: AAV, Lentiviral
Capacity assessment: 58.0/100

Clinical Activity 49 studies

NCT07168785 [18F]-AraG PET Imaging in LA HNSCC EARLY_PHASE1 Not Yet Recruiting NCT07761910 Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for... PHASE2 Recruiting NCT06725550 Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0 NA Recruiting NCT07708714 Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In... PHASE1/PHASE2 Recruiting NCT07640139 Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes NA Enrolling By Invitation NCT06915038 ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the Oropharynx NA Recruiting NCT06508827 Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma PHASE2 Withdrawn NCT06513663 Exercise as Maintenance Therapy in Advanced Lung Cancer NA Terminated NCT05757843 Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab PHASE2 Withdrawn NCT05899166 Carbohydrate Beta Cell Function and Glucose Control in Children With Diabetes NA Recruiting NCT05460468 Neuromodulation of Memory in Aging NA Recruiting NCT06511453 Acupressure in Patients With Sickle Cell Disease NA Active Not Recruiting NCT04402593 Music Therapy For The Treatment Of Cisplatin Induced Tinnitus In Patients... NA Withdrawn NCT05783297 Midwest TXTXT Scale up of an Evidence-Based Intervention to Promote HIV... NA Completed NCT05100342 Prospective Validation of a Points Score System Predicting 30-day Survival NA Recruiting NCT05119036 Adjuvant Treatment Deintensification After Transoral Surgery for Human... NA Completed NCT05251337 Use of Aromatherapy to Reduce Symptom Burden PHASE2 Completed NCT03321760 SABR for T1-2a N1 NSCLC PHASE2 Withdrawn NCT04930055 Immune Responses in Oncology Patients to Novel Coronavirus Vaccines (IROC) NA Terminated NCT05045820 Integrative Medicine in Pain Management in Sickle Cell Disease NA Active Not Recruiting
+ 29 more studies
Source: ClinicalTrials.gov · Retrieved Nov 21, 2026

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Frequently Asked Questions About Indiana University Vector Production Facility

How many clinical programs is Indiana University Vector Production Facility linked to?
Indiana University Vector Production Facility is associated with 49 clinical trials in CDMO Signal's ClinicalTrials.gov-sourced data.
What is Indiana University Vector Production Facility's CDMO Signal Score?
Indiana University Vector Production Facility has a Signal Score of 66/100, based on quality, operations, financial stability, and capacity data.
Evaluating Indiana University Vector Production Facility for a manufacturing program?
Use the free AI matchmaker to compare Indiana University Vector Production Facility against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
AAV CDMOs → Lentiviral CDMOs →

Similar CDMOs

Genezen
Indianapolis, IN · Lexington, MA
Signal Score: 78.1
AAV, Lentiviral
Pharmaron
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
Signal Score: 86.9
AAV, Lentiviral, Plasmid, mAb, Antibody, Recombinant Protein, Biosimilars
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
ReciBioPharm
Keele, UK · Sodertalje, SE
Signal Score: 82.9
AAV, Lentiviral, Plasmid, mRNA
BioReliance (Merck)
Glasgow, UK · Rockville, MD
Signal Score: 80.3
AAV, Lentiviral, Biologics

Compare Indiana University Vector Production Facility with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Indiana University Vector Production Facility
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.